Exelixis
EXEL
#2109
Rank
C$10.22 B
Marketcap
$35.84
Share price
-1.53%
Change (1 day)
23.67%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) Fails to deliver data

Key failure to deliver metrics for Exelixis:

A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.

Failures to deliver for Exelixis (EXEL) - 3 months history

Number of shares, 3 months chart

Biweekly Failures to deliver volume for Exelixis (EXEL) - since 2013

Volume in USD (price x number of shares), data since 2013

Exelixis (EXEL) Failure to deliver volume, Year over Year

Year Volume (Price x Shares) Change
2024C$8.96 M38.21%
2023C$6.48 M-41.81%
2022C$11.14 M-31.9%
2021C$16.36 M-20.71%
2020C$20.64 M303.63%
2019C$5.11 M-70.5%
2018C$17.33 M8.82%
2017C$15.92 M-17.35%
2016C$19.27 M-75.68%
2015C$79.23 M19.37%
2014C$66.37 M258.49%
2013C$18.51 M

FTD volume in the last 3 months for similar companies or competitors

Company FTD volume (3months) FTD volume (1 year) Country
C$22.53 MC$43.31 M๐Ÿ‡ฌ๐Ÿ‡ง UK
C$3.41 MC$70.14 M๐Ÿ‡ซ๐Ÿ‡ท France
C$39.92 MC$95.81 M๐Ÿ‡บ๐Ÿ‡ธ USA
C$36.47 MC$0.31 B๐Ÿ‡บ๐Ÿ‡ธ USA
C$87.32 MC$0.26 B๐Ÿ‡บ๐Ÿ‡ธ USA
C$90.55 MC$0.28 B๐Ÿ‡บ๐Ÿ‡ธ USA
C$0.24 BC$0.50 B๐Ÿ‡บ๐Ÿ‡ธ USA
N/AC$0.06 M๐Ÿ‡บ๐Ÿ‡ธ USA
N/AC$0.04 M๐Ÿ‡บ๐Ÿ‡ธ USA